gms | German Medical Science

86th Annual Meeting of the German Society of Oto-Rhino-Laryngology, Head and Neck Surgery

German Society of Oto-Rhino-Laryngology, Head and Neck Surgery

13.05. - 16.05.2015, Berlin

Article

Send article

LRP1 is differentially expressed in HPV negative and HPV positive head and neck squamous cell carcinoma (HNSCC)

Meeting Abstract

Search Medline for

  • corresponding author Marlen Kolb - HNO-Universitätsklinik Leipzig, Leipzig
  • Gunnar Wichmann - HNO-Universitätsklinik, Universitätsklinikum Leipzig, Leipzig
  • Gerd Birkenmeier - Institut für Biochemie, Medizinische Fakultät, Universität Leipzig, Leipzig
  • Andreas Dietz - HNO-Universitätsklinik, Universitätsklinikum Leipzig, Leipzig

Deutsche Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie. 86. Jahresversammlung der Deutschen Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie. Berlin, 13.-16.05.2015. Düsseldorf: German Medical Science GMS Publishing House; 2015. Doc15hnod215

doi: 10.3205/15hnod215, urn:nbn:de:0183-15hnod2155

Published: March 26, 2015

© 2015 Kolb et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License. You are free: to Share - to copy, distribute and transmit the work, provided the original author and source are credited. See license information at http://creativecommons.org/licenses/by-nc-nd/3.0/.

Outline

Text

Introduction: LRP1 is a potential prognostic marker in several cancer entities since its lowered expression is associated with worth overall survival (OS). Moreover, LRP1 expression was associated with p53 and p16 alteration, serpin-protease-complex-clearance, high-grade and aggressiveness in other tumour entities – all characteristics of HNSCC.

Methods: After detection of LRP1 and a truncated splice variant (shLRP1) in the HNSCC-derived cell lines FaDu and HN5, RNA of 10 primary HNSCC with identical TNM status (pT4a pN2b cM0) at time of diagnosis, but despite identical treatment different clinical course regarding either A) a rather short progression-free (PFS) and overall survival (OS) of the patients (n=5) or B) so far event-free survival of the patients (n=5) were analyzed for presence of both LRP1 transcripts and HPV DNA status was assessed.

Results: We found no difference in LRP1 expression in comparison of groups A and B but significant higher LRP1 expression in HPV DNA-positive HNSCC (n=5). The shLRP1 expression analysis, however, did neither differ in comparison of the two groups with different clinical outcome nor between HPV negative and positive HNSCC.

Conclusion: LRP1 is differentially expressed in HPV negative and positive HNSCC. Considering its association with HNSCC characteristics and in particular HPV-related effects on p53 and p16, further experiments are now performed to corroborate LRP1 as a prognostic marker or therapeutic target in HNSCC.

Der Erstautor gibt keinen Interessenkonflikt an.